Colossal Biosciences, a Dallas-based biotech company, is making significant strides in reviving the Tasmanian tiger, or thylacine, which has been extinct since 1936. The scientists have reconstructed 99.9% of the thylacine's genome using DNA extracted from a well-preserved specimen that has been in ethanol for over a century. This genome reconstruction is expected to provide a detailed blueprint for potential de-extinction efforts, allowing the species to be reintroduced into its native habitat in Australia. The project aims to address biodiversity loss and restore ecological balance by potentially controlling invasive species. While challenges remain in ensuring the viability of the genetic material and its implantation into a surrogate species, the advancements suggest a promising future for de-extinction initiatives. The success of this project could pave the way for similar efforts targeting other extinct species, including the woolly mammoth.